


Tickers: **BUFSX** | **BUISX****MORNINGSTAR RATING**

Overall Morningstar Rating™ of BUFSX based on risk-adjusted returns among 522 Small Growth funds as of 3/31/2026.

FUND MANAGEMENT**Bob Male, CFA**

Manager since Inception
37 Years Investment Experience

MBA - Southern Methodist
B.S. - University of Kansas

**Craig Richard, CFA**

Manager since 2023
24 Years Investment Experience

MBA - University of Kansas
B.S. - Kansas State University

ABOUT US

The Buffalo Funds are a family of 10 actively-managed, no-load mutual funds, which provide a variety of long-term investment options for investors. We believe that patient investing, backed by solid, intelligent research, can be the best way to achieve long-term financial returns.

CONTACT US

800.492.8332
buffalofunds.com

1 Would you please discuss the performance of small-cap growth stocks in the first quarter of 2026?

Small-cap growth stocks experienced a volatile start to 2026, with strong early gains giving way to broader weakness as the quarter progressed. The Russell 2000 Growth Index began the year on a positive note, supported by solid earnings expectations, improving relative valuations versus large caps, and optimism around potential interest rate cuts.

However, sentiment shifted mid-quarter as new developments in artificial intelligence, particularly around “agentic AI,” created uncertainty across parts of the technology sector, especially software companies. Investors began reassessing their long-term growth assumptions regarding various stocks, contributing to heightened volatility. Geopolitical developments including the conflict in Iran later in the quarter added further pressure on equity markets.

For the three months ended March 31, 2026, the small-cap Russell 2000 Growth Index declined 2.81%, outperforming both the Russell Midcap Growth Index and the large-cap Russell 1000 Growth Index, which declined 6.35% and 9.78%, respectively.

2 Would you please discuss any merger & acquisition (M&A) activity that impacted the Fund’s holdings in the first quarter?

We are pleased to report that M&A activity meaningfully impacted the Fund’s performance in the first quarter, with several portfolio holdings involved in takeout transactions. Silicon Laboratories, OneStream, and SkyWater Technology were all acquired during the period, each at a premium to prior trading levels.

The most significant transaction was Silicon Laboratories, which agreed to be acquired by Texas Instruments in an all-cash deal at a substantial premium. This transaction highlights the strategic value of differentiated semiconductor assets, particularly those with strong positions in microcontrollers and connectivity solutions.

More broadly, the increase in M&A activity reflects improving corporate confidence and the willingness of strategic and financial buyers to acquire high-quality growth businesses. We believe the Fund’s portfolio is comprised of companies with strong underlying fundamentals operating in attractive niches, many of which could emerge as compelling acquisition targets over time.

3 How does the profitability of portfolio companies compare with the Russell 2000 Growth Index?

Profitability remains a key differentiator for the Fund. As of quarter-end, approximately 95% of the portfolio was profitable.

This compares favorably to the Russell 2000 Growth Index, where roughly 73% of the index by capitalization weighting consists of companies with positive earnings. The difference is predominately driven by the Fund's lower exposure to riskier early-stage healthcare and biotechnology companies.

While we selectively invest in small positions of earlier-stage healthcare opportunities, our approach emphasizes companies with established business models, commercial products, and a clear path to profitability. We believe this focus on earnings and cash flow provides greater resilience, particularly in periods when capital sources become more selective and fundamentals are increasingly rewarded.

4 Is there a recent portfolio addition you would like to highlight?

One recent addition we would highlight is Arcutis Biotherapeutics, a dermatology-focused biopharmaceutical company with a differentiated non-steroidal treatment platform. Its lead product, ZORYVE, targets common inflammatory skin conditions such as atopic dermatitis and plaque psoriasis, which affect a large portion of the population.

Historically, treatment has relied on steroid-based therapies, which can carry side effects with long-term use. Arcutis' non-steroidal alternative offers strong efficacy with a favorable safety profile and is gaining traction among dermatologists.

The opportunity is supported by a large addressable market and significant room for adoption, as non-steroidal treatments remain underpenetrated relative to traditional therapies. The company is delivering strong revenue growth and attractive margin potential, with meaningful incremental profitability as it scales.

We believe Arcutis exemplifies our approach to healthcare investing: focusing on companies with differentiated products, large market opportunities, and clear paths to long-term value creation.

PERFORMANCE (%) AS OF 3/31/2026

| Average Annual Returns | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Since Inception |
|--|--------------|-------------|-------------|--------------|-------------|-----------------|
| Investor Class - BUFSX | -4.24 | 6.11 | 0.12 | -6.00 | 9.45 | 10.15 |
| Institutional Class - BUISX¹ | -4.21 | 6.22 | 0.21 | -5.91 | 9.59 | 10.31 |
| Russell 2000 Growth Index | -2.81 | 23.58 | 12.27 | 1.62 | 9.79 | 6.50 |
| Morningstar Small Growth Cat. Avg. | -2.07 | 18.45 | 9.83 | 1.24 | 10.51 | - |

Expense Ratio: BUFSX 0.89%, BUISX 0.87%

Inception dates: BUFSX 4/14/1998, BUISX 7/1/2019. Average annual total return represents past performance and is no guarantee of future results. Investment return and principal value will fluctuate and redemption value may be more or less than original cost. Fund performance current to the most recent month-end may be lower or higher than the performance quoted and can be obtained by visiting buffalofunds.com. ¹For performance prior to 7/1/19 (Inception Date of Institutional Class), performance of the Investor Class shares is used and includes expenses not applicable to and higher than those of the Institutional Class shares.

The Fund's investment objectives, risks, charges, and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the investment company and may be obtained by calling 800.492.8332 or visiting buffalofunds.com. Read them carefully before investing.

Mutual fund investing involves risk. Principal loss is possible. The Fund invests in small and mid-cap companies, which involve additional risks such as limited liquidity and greater volatility than large-cap companies. The Fund invests in foreign securities which involve greater volatility and political, economic, and currency risks as well as differences in accounting methods.

The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a 3-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's

March 31, 2026

BUFFALO SMALL CAP GROWTH FUND



monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating™ for a managed product is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating™ metrics. The weights are: 100% 3-year rating for 36-59 months of total returns, 60% 5-year rating/40% 3-year rating for 60-119 months of total returns, and 50% 10-year rating/30% 5-year rating/20% 3-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent 3-year period actually has the greatest impact because it is included in all 3 rating periods. The Buffalo Small Cap Growth Fund (BFSX) received 1 star among 522 for the 3-year, 1 star among 500 for the 5-year, and 2 stars among 399 Small Growth funds for the 10-year period ending 3/31/2026 based on risk-adjusted returns. © 2026 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance is no guarantee of future results.**

The Russell 2000 Growth Index is an unmanaged index that measures the performance of those Russell 2000 Index companies with higher price-to-book ratios and higher forecasted growth values. The Russell Midcap Growth Index measures the performance of the midcap growth segment of the US equity universe. It includes those Russell Midcap Index companies with relatively higher price-to-book ratios, higher I/B/E/S forecast medium term (2 year) growth and higher sales per share historical growth (5 years). The Russell 1000 Growth Index measures the performance of the large-cap growth segment of the US equity universe. It includes those Russell 1000 companies with relatively higher price-to-book ratios, higher I/B/E/S forecast medium term (2 year) growth and higher sales per share historical growth (5 years). It is not possible to invest directly in an index. Revenue growth is the increase (or decrease) in a company's sales from one period to the next. Revenue Growth is not a measure of future performance.

Holdings in the Fund as a percentage of net assets as of 12/31/2025: Silicon Laboratories 1.81%, OneStream 1.01%, SkyWater Technology 0.87%, Texas Instruments 0.00%, and Arcutis Biotherapeutics 0.72%. Fund holdings are subject to change and should not be considered a recommendation to buy or sell any security. Holdings for the quarter are not disclosed until 60 days after quarter end.

Kornitzer Capital Management is the adviser to the Buffalo Funds, which are distributed by Quasar Distributors, LLC.